Ultrasensitive Insulin ELISA

(10-1132-01)

Kit format: 1 x 96 wells

Measurement range: 0.15 - 20 mU/L (0.0065 - 0.87 µg/L)

The Ultrasensitive Insulin ELISA is calibrated against 1st International Reference Preparation 66/304 for human insulin

No cross-reactivity to C-peptide or Proinsulin des(31-32) or split (32-33)

Insignificant or no cross-reactivity to insulin analogs

CE/IVD labeled on select markets

Serum controls available: 10-1134-01 (US only) or 10-1164-01

TALK TO A PERSON

Description

The Ultrasensitive Insulin ELISA is a high quality immunoassay for specific quantification of low levels of human insulin in serum or plasma.

The Mercodia Ultrasensitive Insulin ELISA has little or no cross-reactivity to insulin analogs, rat or mouse insulin, which enables distinguishing endogenous human insulin, both in patients undergoing treatment with insulin analogs, and in rat or mouse models. The Mercodia Insulin ELISAs are the only ELISA assays to satisfy the total error requirements in the Insulin Standardization Program.

Mercodia Diabetes Antigen Control (10-1134-01 (US only) or 10-1164-01) is designed to be used as a two-level control in the Ultrasensitive Insulin ELISA.

Test characteristics

Species

Human

Samples

Serum, plasma

Sample volume

25 µL

Assay range

0.15 - 20 mU/L (0.0065 - 0.87 µg/L)

Detection limit

≤ 0.15 mU/L (0.0065 µg/L)

Incubation

1 h + 30 min

Detection method

Absorbance

specificity

The following cross-reactions have been tested:

C-peptide

<0.01 %

Proinsulin

<0.01 %

Proinsulin des (31-32)

<0.5 %

Proinsulin split (32-33)

<0.5 %

Proinsulin des (64-65)

98 %

Proinsulin split (65-66)

56 %

Insulin aspart

3 %

Insulin detemir

Not detected

Insulin glargin

12 %

Insulin glulisine

Not detected

Insulin lispro

Not detected

IGF-I

<0.02 %

IGF-II

<0.02 %

Rat insulin

0.7 %

Mouse insulin

0.3 %

Porcine insulin

93 %

Ovine insulin

48 %

Bovine insulin

31 %

directions for use & Safety Data Sheet

Directions for Use - 10-1132-01 Version 15.0 Lot.no 32278, 32600, 33448, 35009, 35104

Safety Data Sheet - 10-1132-01

For other languages and older versions:

Technical Library

references

Straniero, S. et al. (2017) Acute caloric restriction counteracts hepatic bile acid andcholesterol deficiency in morbid obesity. J. Intern. Med. 281, 507–517. Read more >

Bojar, D., Scheller, L., Hamri, G. C.-E., Xie, M. & Fussenegger, M. (2018) Caffeine-inducible gene switches controlling experimental diabetes. Nat. Commun. 9, 2318. Read more >

Veluthakal, R. et al. (2018) Restoration of glucose-stimulated Cdc42-PAK1 activation and insulin secretion by a selective Epac activator in type 2 diabetic human islets. Diabetes 67, 199–2011. Read more >